Recce Pharmaceuticals Ltd banner

Intrinsic Value

The intrinsic value of Recce Pharmaceuticals Ltd (RECEF) under the Base Case is 0.37 USD per share. Compared with the current market price of 0.22 USD, the stock appears Undervalued by 41% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

RECEF Intrinsic Value
$0.37
Undervaluation 41%
Intrinsic Value
Price $0.22
Alert me when RECEF is below its intrinsic value
Today $0.19 · 14.9% below the current price

RECEF is cheaper than usual. It was this cheap or cheaper on just 1% of days in the past 4 years.

Alternatives to RECEF

Fundamental Analysis

What Recce Pharmaceuticals Does

Pharmaceuticals Health Care

Recce Pharmaceuticals is an Australian drug-development company focused on new treatments for serious infections. Its main work is to design and test synthetic anti-infective drugs aimed at bacteria, viruses, and fungi, especially infections that are hard to treat with existing medicines. The company is still in development mode, so it does not sell a broad portfolio of approved drugs like a big pharma company would.

Headquarters
Australia AU
IPO date
Jan 15, 2016
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue RECEF Research

Decided on Recce Pharmaceuticals? Get an email when RECEF reaches the price you’d buy at. Free with an account.

Other Recce Pharmaceuticals listings

What is the Intrinsic Value of one RECEF stock?

The intrinsic value for Recce Pharmaceuticals Ltd (RECEF) under the Base Case is 0.37 USD.

Is RECEF stock undervalued or overvalued?

Compared with the current market price of 0.22 USD, the stock appears Undervalued by 41% .

How reliable are our estimates? See how past valuations played out
Back to Top